



NZX/ASX release

3 August 2016

### **Scheme of Arrangement compensatory dividend expected to be paid**

Nuplex Industries (Nuplex, NZX/ASX code: NPX) today confirmed that Nuplex shareholders are expected to receive the per day compensatory dividend referred to in Nuplex's announcement of 23 June 2016. This is because the sole reason the proposed Scheme of Arrangement (the Scheme) between Nuplex and Allnex New Zealand Limited (Allnex) was not implemented on 2 August 2016 was that it had not received antitrust approval from the European Commission (EC).

Allnex continues to expect antitrust approval from the EC will be granted by the first week of September 2016.

#### **Compensatory dividend key details**

- NZ 0.075 cents per share.
- Will be payable for each day by which implementation of the Scheme is delayed solely as a result of obtaining EC antitrust approval from and including today
- The record date for the dividend is expected to be 7.00 pm NZT on the date four business days after the date on which EC antitrust approval is granted, and is expected to be paid three business days after the record date.

Currently, completion is expected to occur in mid-September 2016, following the receipt of EC approval in early September 2016. Nuplex will provide a further update once the exact timetable is known.

*Ends*

#### **For more information regarding Nuplex**

<b>Investors</b>	<b>New Zealand media</b>	<b>Australian media</b>
Josie Ashton, Nuplex +612 8036 0906 <a href="mailto:josie.ashton@nuplex.com">josie.ashton@nuplex.com</a>	Louisa Jones, Porter Novelli +64 21 299 2628 <a href="mailto:louisaj@porternovelli.kiwi">louisaj@porternovelli.kiwi</a>	Paula Hannaford, Kreab +61 2 9552 8936 <a href="mailto:phannaford@kreab.com">phannaford@kreab.com</a>

#### **For more information regarding Allnex**

<b>Company enquiries</b>	<b>New Zealand media</b>	<b>Australian media</b>
Stéphanie Heng, Allnex +32 2 560 4630 <a href="mailto:stephanie.heng@allnex.com">stephanie.heng@allnex.com</a>	Jane Sweeney, Anthem +64 21 910 008 <a href="mailto:jane@anthem.co.nz">jane@anthem.co.nz</a>	Ashley Rambukwella, FCR +61 407 231 282 <a href="mailto:a.rambukwella@fcr.com.au">a.rambukwella@fcr.com.au</a>

## **About Nuplex**

Nuplex is a leading, global manufacturer of resins used in paints, coatings and structural materials with annual sales of c.NZ\$1.5 billion (c.US\$1 billion). Listed on the NZX and the ASX, Nuplex is a global leader in rheology control coatings technology, as well as performance and industrial coating resins, particularly for Automotive OEM, Vehicle Re-finish, Wood, and Protective coatings. From its 16 production sites located across Asia, Europe, America and Australia and New Zealand, Nuplex has customers in over 80 countries worldwide. Through its global R&D network of local technical service support, regional R&D centers and a dedicated Innovation Centre in The Netherlands, Nuplex works in partnership with its customers to develop the right solution for their coatings challenges.

## **About Allnex**

Allnex, formerly Cytec Industries' Coating Resins business and acquired by Advent in 2013 for US\$1.15 billion, with sales of c. US\$1.5 billion, is a leading global producer of coating resins and additives for architectural, industrial, protective, automotive and special purpose coatings and inks. Allnex is recognized as a specialty chemicals pioneer and offers an extensive range of products including innovative liquid resins & additives, radiation cured and powder coating resins & additives and cross linkers for use on wood, metal, plastic, and other surfaces. Today, Allnex has EBITDA of about US\$220 million and has a strong global presence with 17 manufacturing sites and 12 research & technology support facilities throughout the world, focusing on assisting its c.3,000 customers to rapidly bring advanced coating solutions to market.

## **About Advent International**

Founded in 1984, Advent International is one of the largest and most experienced global private equity firms and a leading investor in the global Chemicals industry. Advent's investment philosophy is centred around supporting leading management teams and providing resources for further growth, in order to execute on a mutually developed strategy and investment case. To date, Advent has raised cumulative capital of c.US\$40 billion, and has executed over 310 transactions including over 30 investments in the Chemicals industry. Advent has a strong track record of making significant and successful investments, with recent chemicals transactions including Allnex (formerly Cytec Industries' Coating Resins business), Oxea, Maxam and Grupo Transmerquim. Advent also has extensive experience in conducting Public-to-Private transactions, with recent examples including Douglas, Mediq and Unit 4.